Document Type

Patent

Publication Date

December 2014

Patent Number

8901086

CPC

A61K 39/39558(20130101), A61K 31/7064(20130101)

Abstract

This invention encompasses combination therapies including TCN, TCN-P, TCN-PM and/or related compounds and one or more additional anti-cancer agents, for example, taxanes a molecule that modulates the HER2/neu (erbB2) receptor, anthracyclin compounds, epidermal growth factor receptor inhibitor compounds, one or more platinum compounds and bortezomib and derivatives thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.

Application Number

13/463,576

Assignees

University of South Florida

Filing Date

05/03/2012

Primary/U.S. Class

514/23

Share

COinS